NEWCASTLE, Australia & EDEN PRAIRIE, Minn. — VenstraMedical, a cardiovascular medical device company, has received an investment from Highcroft Capital, a Minnesota-based venture capital firm focused on MedTech innovation. The funding will accelerate development of VenstraMedical’s next-generation percutaneous ventricular assist device (pVAD), a low-profile, full-flow support system designed to deliver complete ventricular unloading for patients in cardiogenic shock or undergoing high-risk coronary procedures.
“We’ve been highly impressed with VenstraMedical’s team and technology,” said Dr. Peter Eckman, Partner at Highcroft Capital. “As a physician-led group, we’re excited to support a system that could transform cardiac care through improved performance, safety, and ease of use.”
VenstraMedical’s catheter-based pump, protected by eight issued patents, collapses into a 9-French catheter for minimally invasive insertion. Once deployed, it delivers up to 7 L/min of cardiac output, providing full ventricular unloading and stabilizing hemodynamics during critical interventions.
“Support from experienced cardiologists and users of pVAD technology validates our approach and accelerates our path toward clinical trials,” said Dr. Martin Cook, Co-founder and Chief Executive Officer of VenstraMedical.
The new investment follows publication of VenstraMedical’s preclinical findings in the ASAIO Journal, a presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference, and a $1 million grant from MTPConnect’s Targeted Translation Research Accelerator (TTRA) under Australia’s Medical Research Future Fund. With the global pVAD market exceeding US$2 billion annually, VenstraMedical aims to redefine temporary mechanical circulatory support with its innovative, low-profile device design.
